These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group. Block G; Liss C; Reines S; Irr J; Nibbelink D Eur Neurol; 1997; 37(1):23-7. PubMed ID: 9018028 [TBL] [Abstract][Full Text] [Related]
3. Controlled-release carbidopa/levodopa (CR) in parkinsonian patients with response fluctuations on standard levodopa treatment: clinical and pharmacokinetic observations. Deleu D; Jacques M; Michotte Y; Ebinger G Neurology; 1989 Nov; 39(11 Suppl 2):88-92; discussion 95. PubMed ID: 2685654 [TBL] [Abstract][Full Text] [Related]
4. Early morning akinesia in Parkinson's disease: effect of standard carbidopa/levodopa and sustained-release carbidopa/levodopa. Pahwa R; Lyons K; McGuire D; Dubinsky R; Hubble JP; Koller WC Neurology; 1996 Apr; 46(4):1059-62. PubMed ID: 8780091 [TBL] [Abstract][Full Text] [Related]
5. Comparison of standard carbidopa-levodopa and sustained-release carbidopa-levodopa in Parkinson's disease: pharmacokinetic and quality-of-life measures. Pahwa R; Lyons K; McGuire D; Silverstein P; Zwiebel F; Robischon M; Koller WC Mov Disord; 1997 Sep; 12(5):677-81. PubMed ID: 9380047 [TBL] [Abstract][Full Text] [Related]
6. Controlled release levodopa-carbidopa (CR-5) in the management of parkinsonian motor fluctuations. Juncos JL; Fabbrini G; Mouradian MM; Chase TN Arch Neurol; 1987 Oct; 44(10):1010-2. PubMed ID: 3632371 [TBL] [Abstract][Full Text] [Related]
7. [Clinical experience in switching patients from standard levodopa to a controlled-release levodopa]. Leiva Santana C; Galvañ Berenguer B; Gómez García J; Cabello López J Neurologia; 1996 Jan; 11(1):1-9. PubMed ID: 8714169 [TBL] [Abstract][Full Text] [Related]
8. [Direct switch from conventional levodopa to stalevo (levodopa/carbidopa/entacapone) improves quality of life in Parkinson's disease: results of an open-label clinical study]. Litvinenko IV; Odinak MM; Mogil'naia VI; Sologub OS; Sakharovskaia AA Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(1):51-4. PubMed ID: 19156087 [TBL] [Abstract][Full Text] [Related]
12. Conversion to carbidopa and levodopa extended-release (IPX066) followed by its extended use in patients previously taking controlled-release carbidopa-levodopa for advanced Parkinson's disease. Tetrud J; Nausieda P; Kreitzman D; Liang GS; Nieves A; Duker AP; Hauser RA; Farbman ES; Ellenbogen A; Hsu A; Kell S; Khanna S; Rubens R; Gupta S J Neurol Sci; 2017 Feb; 373():116-123. PubMed ID: 28131167 [TBL] [Abstract][Full Text] [Related]
13. Controlled-release carbidopa/levodopa in the treatment of Parkinsonism. Hutton JT; Dippel RL; Bianchine JR; Strahlendorf HK; Meyer PG Clin Neuropharmacol; 1984; 7(2):135-9. PubMed ID: 6375861 [TBL] [Abstract][Full Text] [Related]
14. Comparison of orally dissolving carbidopa/levodopa (Parcopa) to conventional oral carbidopa/levodopa: A single-dose, double-blind, double-dummy, placebo-controlled, crossover trial. Ondo WG; Shinawi L; Moore S Mov Disord; 2010 Dec; 25(16):2724-7. PubMed ID: 20925074 [TBL] [Abstract][Full Text] [Related]
15. Treatment of early Parkinson's disease with controlled-release levodopa preparations. Rinne UK; Rinne JO Neurology; 1989 Nov; 39(11 Suppl 2):78-81; discussion 95. PubMed ID: 2586766 [TBL] [Abstract][Full Text] [Related]
16. Effect of controlled-release carbidopa/levodopa on motor performance in advanced Parkinson's disease. Rondot P; Ziegler M; Aymard N; Teinturier A Neurology; 1989 Nov; 39(11 Suppl 2):74-7; discussion 95. PubMed ID: 2586765 [TBL] [Abstract][Full Text] [Related]
17. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses. Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222 [TBL] [Abstract][Full Text] [Related]
18. Controlled-release Sinemet (CR-4): a double-blind crossover study in patients with fluctuating Parkinson's disease. Ahlskog JE; Muenter MD; McManis PG; Bell GN; Bailey PA Mayo Clin Proc; 1988 Sep; 63(9):876-86. PubMed ID: 3045435 [TBL] [Abstract][Full Text] [Related]
19. Controlled-release carbidopa-levodopa (Sinemet) in combination with standard Sinemet in advanced Parkinson's disease. Mark MH; Sage JI Ann Clin Lab Sci; 1989; 19(2):101-6. PubMed ID: 2665626 [TBL] [Abstract][Full Text] [Related]
20. A multicenter, open-label, sequential study comparing preferences for carbidopa-levodopa orally disintegrating tablets and conventional tablets in subjects with Parkinson's disease. Nausieda PA; Pfeiffer RF; Tagliati M; Kastenholz KV; DeRoche C; Slevin JT Clin Ther; 2005 Jan; 27(1):58-63. PubMed ID: 15763606 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]